Genelux Corporation Set to Join the Russell 3000 and Russell 2000 Indexes Effective June 26, 2023
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux
Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000 Index and small-cap Russell 2000 at the
conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.
Every year FTSE Russell conducts updates to its various indexes based on total market capitalization and style attributes. Membership in the U.S. all-cap Russell 3000 Index remains in place for one year and means automatic inclusion in the appropriate growth and value style indexes, which is the small-cap Russell 2000 Index for Genelux. The 2023 index showed noteworthy growth in the health care industry, with a majority of the companies moving from small-cap to large-cap coming from the health care space.
“Our inclusion in these Russell indexes is a reflection of not just the market's recognition of our recent clinical successes, but also the potential that lies within Olvi-Vec” said Thomas Zindrick, President, CEO and Chairman of Genelux. “Our inclusion among larger market cap companies should help to increase investor awareness, expand institutional ownership, and provide additional liquidity in our stock.”
For further information on the Russell 2000 Index and the Russell indexes reconstitution, please find the “Russell Reconstitution” section on the FTSE Russell website.
Lesen Sie auch
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients
suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of
the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3
registrational trial evaluating the efficacy and safety of Olvi-Vec in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux' discovery and development efforts revolves
around the company's proprietary CHOICE platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates,
including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter
@Genelux_Corp and on LinkedIn.